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INTRODUCTION
The prescription of medication is the most 
common form of medical treatment in 
primary care and over 900 million items are 
dispensed in the community in England each 
year.1 Prescribing is therefore an essential 
skill for GPs. For every prescribing decision, 
the potential for benefit needs to be balanced 
against the risk of harm. The prescriber 
must use clinical knowledge to apply 
bodies of evidence, rules, and guidance to 
a prescribing decision, while also taking into 
account the patient’s view. The challenge 
of prescribing has increased, owing to the 
increased complexity of medical care, and 
the treatment of older and more severely ill 
patients.2 Errors can occur in this process. 
In primary care, published error rates per 
prescription item vary from less than 1%,3 to 
over 40%,4 the latter being a Swedish study 
where failure to document the indication 
for a drug was considered an error. Such 
variation in error rates is likely to be 
significantly affected by the definition of error 
and the rigour with which error detection 
is undertaken. Nevertheless, prescribing 
errors in primary care are a preventable 
source of harm, with a systematic review 
showing that they account for around 3.7% 
of hospital admissions.5
Relatively little is known about prescribing 
errors in general practice, or the factors 
associated with error. In one study, 
prescriptions were screened by community 
pharmacists for prescribing errors; 
prescribing errors were identified in 7.5% 
of prescribed items.6 A study in care homes 
showed that 39% of 256 residents had one 
or more prescribing errors, with 8.3% of 
prescription items (or intended prescription 
items) affected.7 According to the UK’s 
National Patient Safety Agency, 26% of 
general practice incidents reported to the 
National Reporting and Learning System 
relate to medication,8 and 25% of adverse 
incidents that resulted in litigation claims in 
general practice were a result of medication 
errors, suggesting consequences not only 
for patient safety but also for practitioners.9
Given the paucity of research in this field, 
a large-scale study was conducted, with 
the aim of investigating the prevalence and 
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Relatively little is known about prescribing 
errors in general practice, or the factors 
associated with error.
Aim
To determine the prevalence and nature of 
prescribing and monitoring errors in general 
practices in England.
Design and setting
Retrospective case-note review of unique 
medication items prescribed over a 12-month 
period to a 2% random sample of patients. 
Fifteen general practices across three primary 
care trusts in England.
Method
A total of 6048 unique prescription items 
prescribed over the previous 12 months for 
1777 patients were examined. The data were 
analysed by mixed effects logistic regression. 
The main outcome measures were prevalence 
of prescribing and monitoring errors, and 
severity of errors, using validated definitions.
Results
Prescribing and/or monitoring errors were 
detected in 4.9% (296/6048) of all prescription 
items (95% confidence interval [CI] = 4.4% 
to 5.5%). The vast majority of errors were 
of mild to moderate severity, with 0.2% 
(11/6048) of items having a severe error. 
After adjusting for covariates, patient-related 
factors associated with an increased risk of 
prescribing and/or monitoring errors were: 
age <15 years (odds ratio [OR] = 1.87, 95% 
CI = 1.19 to 2.94, P = 0.006) or >64 years 
(OR = 1.68, 95% CI = 1.04 to 2.73, P = 0.035), and 
higher numbers of unique medication items 
prescribed (OR = 1.16, 95% CI = 1.12 to 1.19, 
P<0.001). 
Conclusion
Prescribing and monitoring errors are common 
in English general practice, although severe 
errors are unusual. Many factors increase 
the risk of error. Having identified the most 
common and important errors, and the factors 
associated with these, strategies to prevent 
future errors should be developed, based on 
the study findings.
Keywords
general practice; medication errors; 
prevalence; primary health care. 
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nature of prescribing and monitoring errors 
in general practice in England, along with 
the factors associated with errors.
METHOD
Setting and selection of general practices
Three English primary care trusts (PCTs) 
with differing characteristics (inner-city 
London, urban, and suburban/rural) were 
approached to act as sites for recruitment 
of general practices. 
Between May and August 2010, all 97 
general practices from these PCTs were 
invited to take part. Thirty replied and 20 
expressed an interest in taking part. A total 
of fifteen were then purposefully selected 
to obtain a wide spread of different types 
of practice.
Sample size calculation
On the basis of previous studies, the best 
estimate for the prescribing error rate 
in primary care was around 8%.6,7 It was 
calculated that if a similar prevalence of 
prescribing errors were to be found in the 
present study, 3750 prescription items 
needed to be reviewed, in order to report this 
with a two-sided 95% confidence interval 
(CI) and accuracy of ±1.6%. This allowed for 
the clustered design and assumed a total 
of 15 practices, an intra-class correlation 
coefficient of 0.01 (based on the authors’ 
previous studies),10 and an average cluster 
size of 250 prescription items reviewed per 
practice.
The records of a 2% random sample 
of patients within each general practice 
were investigated to comfortably exceed the 
target of 3750 prescription items and thus 
increase the precision of the estimate of the 
error rate.
Definitions
The definition of a prescribing error used 
was one originally developed with hospital-
based practitioners:
“A ... prescribing error occurs when, 
as a result of a prescribing decision or 
prescription writing process, there is an 
unintentional, significant  ... reduction in the 
probability of treatment being timely and 
effective or ... increase in the risk of harm 
when compared to generally accepted 
practice.”11
This definition is accompanied by a list of 
examples of what should and should not be 
included as an error.
A monitoring error was defined, based 
on the consensus definition of Alldred et al, 
together with a list of medications that need 
blood-test monitoring and its frequency:
“A monitoring error occurs when a 
prescribed medicine is not monitored in the 
way which would be considered acceptable 
in routine general practice. It includes the 
absence of tests being carried out at the 
[required] frequency ..., with tolerance of 
±50%. ... If a patient refused to give consent 
for a test, then this would not constitute an 
error.”12
For the purposes of this study, a list of 
medications requiring blood-test monitoring 
was used, along with recommended 
monitoring intervals (Box 1).
Identification and classification of 
prescribing and monitoring errors
Data were collected by four pharmacists 
trained by the research team to identify 
potential errors from GP records. Data 
were collected between August 2010 and 
April 2011. The pharmacists undertook a 
retrospective review of unique prescription 
items issued to patients in the 12 months 
prior to the date of data collection (for any 
prescription that was repeated during the 
study period, only the latest of these was 
examined). The pharmacists identified any 
potential prescribing or monitoring errors, 
having taken account of detailed information 
in patients’ medical records relating to 
patient characteristics, comorbidities, other 
medications, allergies, and the need for 
monitoring.
The details of all potential errors were 
discussed by a panel (a GP, a clinical 
pharmacologist, and three pharmacists), 
to decide whether they fitted the error 
definition, taking into account practice in 
primary care, and, if so, how the error 
How this fits in
Prescribing errors are known to be a 
problem in general practice, but estimates 
of prevalence vary widely and little is known 
about the frequency of different types of 
error or the factors associated with error. In 
this study, prescribing or monitoring errors 
were detected in one in 20 prescription 
items and the vast majority were of mild 
to moderate severity. A number of factors 
were associated with prescribing and/or 
monitoring errors; these included age, sex, 
number of unique prescriptions per patient, 
and prescriptions from specific therapeutic 
groups. Having identified the most common 
and important errors, and the factors 
associated with these, it will be possible to 
devise effective strategies for preventing 
errors in the future.
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should be classified in terms of error 
type. In the vast majority of cases, the 
pharmacists who had collected the data 
provided sufficient information for the panel 
to make a judgement. Where this was 
not the case, they were asked to provide 
further details, and to return to the general 
practice if needed. The panel maintained a 
cumulative list of classification decisions to 
ensure consistency throughout the study.
It became apparent that there were some 
problems that did not fit within the error 
definitions, but nevertheless represented 
less than ideal practice. Therefore, 
another category of problem, ‘suboptimal 
prescribing’, was created. The pharmacists 
also identified prescriptions associated 
with legal issues, but that did not fall into 
the definition of error; these were given a 
separate category of ‘legal problem’. Each 
potential error was therefore classified as 
a prescribing error, a monitoring error, 
suboptimal prescribing, legal problem, or 
no problem.
Error severity
The severity of each error, identified using 
a reliable validated 0–10 scale (0 = no risk 
of harm; 10 = death),13 was assessed by 
two GPs, two pharmacists, and one clinical 
pharmacologist. According to this method, 
the mean score across all five judges was 
used as the severity score, where errors 
with scores of <3 were considered minor, 
those between 3 and 7 moderate, and 
scores >7 severe.
Data relating to the characteristics of 
participating general practices
The general practices provided descriptive 
data, including list size (number of patients); 
age–sex breakdown of the practice 
population; number, sex, and types of GPs 
(and other prescribers) in the practice; 
whether the practice was a GP training 
practice, or a dispensing practice; and 
the clinical computer system used in the 
practice. Publicly available sources of data 
(Table 1) were used to obtain deprivation 
scores and Quality and Outcomes 
Framework points for the practices.
Data analysis
Data were entered onto a Microsoft® 
Access® 2007 database, and every item 
was checked by another member of the 
research team. Any data-entry errors were 
corrected and an audit trail was kept.
Categorical variables were described 
using frequencies and percentages, and 
means and standard deviations (SDs) or 
medians and interquartile ranges (IQRs) 
were used to summarise continuous 
variables, depending on their distribution.
The prevalence of prescribing and 
monitoring errors was estimated and 
95% CIs reported. Multivariable analyses, 
modelling the relationships between 
the risk of error and selected predictor 
variables and a priori confounders, were 
performed at the patient level and at the 
prescription level respectively. The primary 
outcome measure was binary, indicating 
the presence of one or more prescribing 
or monitoring errors, and modelled 
using logistic regression. To estimate 
the relationship between prescribing and 
monitoring errors and relevant covariates, 
six logistic regression models were built as 
follows: (1) a univariate model using patient 
and general practice characteristics; (2) 
a multivariable model with all patient and 
general practice characteristics; (3) a 
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Box 1. Medicines requiring blood test monitoring
The following medications were reviewed to determine whether blood-test monitoring had been done 
before or soon after the initiation of therapy (for medication that had recently been started), or as part of 
ongoing maintenance for patients on longer term therapy. 
Monitoring before or soon after the initiation of therapy
Drug/drug group Monitoring requirements
Angiotensin-converting enzyme Renal function and electrolytes before starting therapy, repeated 
  inhibitor/   2 weeks after initiation
Angiotension II receptor antagonists Renal function and electrolytes before starting therapy, repeated  
   2 weeks after initiation
Digoxin Renal function and electrolytes before starting therapy
Diuretics Renal function and electrolytes before starting therapy
Glitazones Liver function tests before starting therapy
Statins Liver function tests before starting therapy
Monitoring of longer-term therapy
Drug/drug group Monitoring requirements
Angiotensin-converting enzyme 12-monthly renal function and electrolytes 
  inhibitor/
Angiotension II receptor antagonists 12-monthly renal function and electrolytes
Amiodarone 6-monthly thyroid function tests
 6-monthly liver function tests
Azathioprine 3-monthly full blood count
Carbimazole 3-monthly thyroid function tests (6-monthly if patient been stabilised  
   for over 1 year)
Digoxin Digoxin level if toxicity or lack of efficacy suspected.
Diuretics 12-monthly renal function and electrolytes
Glitazone 12-monthly liver function tests
Levothyroxine 12-monthly thyroid function tests
Lithium 3-monthly lithium concentration
 12-monthly thyroid function tests
Methotrexate 3-monthly full blood count
 3-monthly liver function tests
 6-monthly renal function and electrolytes
Sulfasalazine Full blood count 3-monthly in first year
 Liver function tests 3-monthly in first year
 Full blood count 6-monthly in second year
 Liver function tests 6-monthly in second year
 No further monitoring if stable
Statin Liver function tests within 3 months, and at 12 months, of  
   starting treatment
Theophylline Theophylline level if toxicity suspected 
Valproate 3-monthly liver function tests for first 6 months
Warfarin 12-weekly International Normalized Ratio
univariate model using prescription and 
prescriber characteristics; (4) a univariate 
model using prescription and prescriber 
characteristics, adjusting for patient 
clustering; (5) a multivariable model with all 
prescription and prescriber characteristics; 
and (6) a multivariable model with all 
prescription and prescriber characteristics, 
adjusting for patient clustering. To take into 
account potential clustering, in models 4 
and 6, patients were treated as random 
effects in a multilevel model to adjust for 
correlation. The significance of the variables 
in the models was assessed using the Wald 
χ2 test and by determination of odds ratios 
(ORs) with associated 95% CIs. Statistical 
significance for all analyses was set at <0.05 
(two-sided). All the statistical analyses were 
performed using STATA (version 11.2), and 
the xtmelogit command used to take into 
account possible clustering (patient).
RESULTS
General practices characteristics
The mean list size of the 15 general 
practices was 5916 (SD = 3014, range = 1600 
to 12 000); 10 (67%) were involved in GP 
training, two (13%) were dispensing, and 12 
(80%) were in an urban area. The practices 
used a range of different clinical computer 
systems.
Compared with figures for England, 
the study practices were reasonably 
representative in terms of list size and 
overall scores in the Quality and Outcomes 
Framework (Table 1), but appeared more 
deprived.
Medical records reviewed and patient 
characteristics
The study involved examination of the 
records of 1777 patients. All practices had 
computerised records and this was the 
main source of information; paper-based 
records (such as hospital correspondence) 
were used if these provided additional 
information. Data were available for all 
patients. These patients had a mean age 
of 39.5 years (SD = 22.6 years), and 49.7% 
(884/1777) were female. The age distribution 
of patients was similar to that of the English 
population for 2010,14 with 16.7% (297/1777) 
aged 0–14 years and 15.9% (283/1777) aged 
≥65 years. Of the 1777 patients, 67.5% 
(1200/1777) had at least one prescription 
during the 12-month retrospective review 
of their records.
The pharmacists reviewed 6048 unique 
prescription items. Of these, 48.4% 
(2929/6048) were acute prescriptions, 51.6% 
(3119/6048) were repeat prescriptions, and 
12.7% (770/6048) were items considered 
to require blood-test monitoring. A clear 
majority of the 6048 prescriptions (80.3% 
[4859/6048]) were issued by GP partners, 
12.9% (779/6048) by salaried GPs, 3.1% 
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Table 2. Distribution of different types of prescribing errors
Types of prescribing error Frequency All errors, %
Incomplete information on prescription 74 30.0
Dose/strength error 44 17.8
Timing error 26 10.5
Frequency error 20 8.1
Omission of concomitant treatment 19 7.7
Unnecessary drug 12 4.9
Contraindication error 12 4.9
Incorrect drug 10 4.0
Duplication 9 3.6
Interaction error 9 3.6
Allergy error 3 1.2
Inadequate documentation in medical records 3 1.2
Quantity error  3 1.2
Formulation error 2 0.8
Generic/brand name error 1 0.4
Total 247 100.0
Type of monitoring error   
  Monitoring not requested 38 69.1 
  Requested but not done 12 21.8 
  Results not available 5 9.1
Total 55 100.0
Table 1. Comparison of characteristics of general practices involved 
in the study with National figures for England
 Mean (SD) across 
Characteristic GP practices studied Mean national figurea
Practice list size 5916 (3014) 6610a
Number of GPs 5 (2.3) 4.73b
Deprivation using IMD 2007 score 30.4 (18.2) 21.7c
QOF medicines management points 99.2% (2.0) 97.2%d 
  per practice, %
QOF total points per practice, % 92.5% (6.8) 93.7%d 
IMD = Index of Multiple Deprivation. QOF = Quality and Outcomes Framework. SD = standard 
deviation. aFigures for England for 2010, obtained from the Health and Social Care Information Centre 
[http://www.hscic.gov.uk/searchcatalogue?productid=10382&topics=2%fPrimary+care+services 
%2fGeneral+practice% 2fGeneral+Practice+workforce&sort=Most+recent&size=10&page=1#top] data 
available in Microsoft Excel Workbook with file name ‘NHS Staff — 2002–2012, General Practice Bulletin 
Tables. bFigures for England for 2010 calculated from data obtained from the Health and Social Care 
Information Centre: total GPs in England: 39 409; total general practices: 8324  ([http://www.hscic.
gov.uk/searchcatalogue?productid=10382&topics=2%fPrimary+care+services%2fGeneral+practice% 
2fGeneral+Practice+workforce&sort=Most+recent&size=10&page=1#top] data available in Microsoft 
Excel Workbook with file name ‘NHS Staff — 2002–2012, General Practice Bulletin Tables. cMean IMD 
score for English lower layer super output areas (available from http://webarchive.nationalarchives.gov.
uk/20100410180038/http://communities.gov.uk/communities/neighbourhoodrenewal/deprivation/deprivation07/). 
d2010 Quality and Outcomes Framework figures for England (available from: http://www.ic.nhs.uk/qof).
(185/6048) by locum GPs, 2.2% (133/6048) by 
GPs in training, and 1.0% (60/6048) by non-
medical prescribers; for 0.5% (33/6048) the 
type of prescriber was not identified.
Prevalence of errors and other problems
From the 6048 prescription items reviewed, 
there was a prevalence of:
• 4.1% (247/6048; 95% CI = 3.6% to 4.6%) 
prescribing errors;
• 0.9% (55/6048; 95% CI = 0.7% to 1.1%) 
monitoring errors;
• 7.1% (427/6048; 95% CI = 6.4% to 7.7%) 
suboptimal prescribing;
• 0.1% (8/6048; 95% CI = 0.06% to 0.3%) 
legal problems.
Restricting analysis to the 770 
prescription items that required blood-
test monitoring showed a prevalence of 
monitoring errors of 6.9% (53/770; 95% 
CI = 5.2% to 8.9%).
The prevalence of prescription items with 
at least one prescribing and/or monitoring 
error was 4.9% (296/6048; 95% CI = 4.4% to 
5.5%), with a small number of prescriptions 
containing more than one error. There 
were 247 prescribing errors and the most 
common types were incomplete information 
on the prescription; dose/strength error; 
and incorrect timing of doses (Table 2). 
There were 55 monitoring errors and the 
most common type was failure to request 
monitoring.
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Box 2. Examples of errors judged to be of different grades of severity
Minor errors
• 1-year old girl prescribed amoxicillin 125 mg/5 ml suspension twice during the same consultation. One 
 was for 2.5 ml three times daily for 1 week, and the other for 5 ml three times daily for 1 week.
• Topical betamethasone 0.1% prescribed in an adult patient. No directions given relating to the 
 frequency of application.
• Betamethasone cream 0.1% prescribed ‘to be applied sparingly for 1 week’ for a 5-year-old child. No 
 frequency of use specified.
• 29-year-old patient prescribed co-amoxiclav tablets 21 × 500 mg/125 mg for sinusitis. Dose and 
 frequency not specified on prescription.
Moderate errors
• 64-year old patient prescribed ibuprofen 400 mg, one tablet to be taken three times daily, after a road 
 accident. No concomitant medication was prescribed for gastric protection. Patient also on aspirin for 
 peripheral vascular disease.
• Indometacin 50 mg prescribed with dosage instructions ‘as directed’, with no instructions on frequency 
 or maximum daily intake. Patient diagnosed with alcoholic cirrhosis of the liver.
• Patient prescribed levothyroxine 25 μg, one tablet to be taken every day. Thyroid function tests were 
 requested but not done.
Severe errors
• 62-year-old patient with documented allergy to penicillin; prescribed a course of oral flucloxacillin.
• Aciclovir 200 mg prescribed, one tablet to be taken five times a day for widespread cold sores, to a 
 patient with a documented severe allergic reaction to aciclovir.
• Older patients on warfarin. Last documented international normalised ratios were more than 2 years 
 previously (n = 7 errors).
• 93-year-old patient prescribed warfarin. Last documented international normalised ratio was more 
 than 1 year previously. Patient did not attend three consecutive anticoagulant appointments, but warfarin 
 prescription continued.
Table 3. Patient-level model of risks associated with prescribing or monitoring errors (n = 1777)
  Univariate models (model 1)   Multivariable models (model 2)
Factor Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Sex       
  Malea 1.00   1.00  
  Female 0.76 0.56 to 1.02 0.064 0.66 0.48 to 0.92 0.013
Number of drugs 1.17 1.13 to 1.20 <0.001 1.16 1.12 to 1.19 <0.001
Age category, years       
  15–64a 1.00   1.00  
  0–14 1.53 0.99 to 2.35 0.053 1.87 1.19 to 2.94 0.006 
  65–74 2.69 1.73 to 4.20 <0.001 1.68 1.04 to 2.73 0.035 
  ≥75 4.26 2.81 to 6.47 <0.001 1.94 1.19 to 3.19 0.008
Dispensing practice       
  Non dispensinga 1.00   1.00  
  Dispensing practice 1.05 0.73 to 1.51 0.781 0.70 0.26 to 1.88 0.476
Training practice 
  Traininga 1.00  1.00    
  Not a training practice 1.33 0.98 to 1.81 0.065 1.39 0.97 to 2.01 0.075
Practice size 
  5000–10 000a 1.00   1.00   
  <5000 patients 0.83 0.58 to 1.17 0.281 0.88 0.58 to 1.34 0.553 
  >10 000 patients 0.74 0.49 to 1.11 0.147 0.56 0.31 to 0.99 0.047
Location    
  Urbana 1.00   1.00  
  Rural practice 1.03 0.74 to 1.44 0.849 1.06 0.43 to 2.58 0.905
aReference group.
For the 12-month data-collection period, 
of the patients who received at least 
one medication, 18.7% (224/1200; 95% 
CI = 16.5% to 21.0%) had at least one 
prescribing and/or monitoring error. For 
patients aged ≥75 years who had received 
at least one medication, the prevalence 
was 41.9% (54/129; 95% CI = 33.2% to 
50.9%). For patients who had received five or 
more medications over the data-collection 
period, the prevalence of error was 32.3% 
(152/471; 95% CI = 28.1% to 36.7%), and 
for patients who had received 10 or more 
drugs, the prevalence was 48.8% (84/172; 
95% CI = 41.2% to 56.6%).
Error severity
Of the 302 prescribing and monitoring 
errors, 42.4% (128/302) errors had scores 
of <3, and were thus deemed to be minor; 
54.0% (163/302) had scores of 3–7 and were 
thus moderate; 3.6% (11/302) had scores >7 
and were thus severe. The median severity 
score was 3.3 (IQR = 2.2 to 4.4, minimum 
0.7, maximum 8.6). The 55 monitoring 
errors had a median score of 3.8; the 247 
prescribing errors had a lower median 
score of 3.0. Examples of errors of different 
severity are shown in Box 2. On the basis of 
the data collected in this study, no patient 
was hospitalised or died as a result of the 
errors detected.
Factors associated with prescribing or 
monitoring errors
Several significant associations were found 
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Table 4. Prescription-level univariate models of risks associated with prescribing or monitoring errors: 
unadjusted and adjusted for patient clustering 
  Univariate unadjusted modela (model 3)   Univariate adjusted modelb (model 4) 
Factor Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Medication on 3.32 2.56 to 4.30 <0.001 3.57 2.68 to 4.75 <0.001 
  monitoring list
Repeat prescriptionc 1.40 1.10 to 1.78 0.006 1.39 1.08 to 1.79 0.011
Formulationd       
  Eye/ear drops 2.01 1.21 to 3.33 0.007 2.08 1.20 to 3.59 0.009 
  Inhalers 0.41 0.21 to 0.81 0.010 0.40 0.20 to 0.79 0.009 
  Injections 0.51 0.24 to 1.10 0.447 0.51 0.23 to 1.11 0.091 
  Liquid oral 0.82 0.49 to 1.38 0.087 0.80 0.46 to 1.38 0.414 
  Rectal 0.80 0.11 to 5.95 0.827 0.97 0.12 to 7.72 0.973 
  Topical 0.98 0.70 to 1.37 0.905 1.00 0.70 to 1.43 0.992
Prescriber typee 
  Salaried GP 0.62 0.41 to 0.95 0.026 0.64 0.4  1 to 1.00 0.051 
  Locum GP 1.07 0.56 to 2.05 0.835 1.12 0.55 to 2.27 0.760 
  Training GP 1.36 0.68 to 2.71 0.380 1.34 0.63 to 2.85 0.441 
  Non-medical prescriber 0.99 0.31 to 3.17 0.982 0.87 0.25 to 3.06 0.832 
  Other/unknown 1.94 0.59 to 6.41 0.277 1.78 0.50 to 6.43 0.358
British National Formulary chapterf      
  Cardiovascular system 5.53 2.66 to 11.49 <0.001    
  Respiratory system 1.58 0.65 to 3.84 0.315    
  CNS 2.06 0.94 to 4.49 0.07    
  Infections 2.37 1.07 to 5.24 0.034    
  Endocrine 2.87 1.23 to 6.73 0.015    
  Obstetrics, gynaecology, 1.09 0.33 to 3.66 0.887 
    urinary tract disorders 
  Malignant disease and 14.00 3.84 to 51.07 <0.001 
    immunosuppression      
  Nutrition and blood 1.17 0.35 to 3.92 0.803    
  Musculoskeletal 6.38 2.87 to 14.21 <0.001    
  Eye 6.61 2.74 to 15.92 <0.001    
  Ear nose and oropharynx 3.50 1.29 to 9.50 0.014    
  Skin 3.52 1.63 to 7.59 0.001    
  Immunology and vaccines 2.18 0.74 to 6.37 0.155  
Computer systemg       
  EMIS PCS 1.15 0.87 to 1.53 0.322 1.17 0.83 to 1.64 0.371 
  Isoft Premiere 0.67 0.45 to 0.98 0.040 0.64 0.40 to 1.00 0.051 
  TPP 1.13 0.79 to 1.63 0.507 1.06 0.68 to 1.65 0.812
CNS = central nervous system. aModel unadjusted for clustering by patient. bModel adjusted for clustering by patient. cAcute prescriptions. dSolid oral medication (pessaries 
category omitted). eGP partner. fGastrointestinal (anaesthesia chapter omitted). gEMIS LV. 
in the patient-level multivariable analysis 
(Table 3). For each additional unique 
medication item that the patient had received 
over the course of the 12-month data-
collection period, there was a significant 
16% increased risk of error (OR = 1.16, 
95% CI =1.12% to 1.19%, P<0.001), and 
women were less likely than men to have a 
prescribing or monitoring error (OR = 0.66, 
95% CI = 0.48 to 0.92, P = 0.013). Compared 
to those aged 15–64 years, patients who 
were <15 years had an 87% excess risk 
of error (OR = 1.87, 95% CI = 1.19 to 2.94, 
P = 0.006); those aged 65–74 years had a 
68% excess risk (OR = 1.68, 95% CI = 1.04 
to 2.73, P = 0.035), and those ≥75 years 
had a 94% excess risk (OR = 1.94, 95% 
CI = 1.19 to 3.19, P = 0.008). There was a 
significant 44% risk reduction in errors in 
practices with more than 10 000 patients 
(OR = 0.56, 95% CI = 0.31 to 0.99, P = 0.047). 
Furthermore, non-training practices had 
borderline significant 39% excess risk of 
errors (OR = 1.39, 95% CI = 0.97 to 2.01, 
P = 0.075) compared to training practices.
The findings from the prescription-level 
model are shown in Table 4 (univariate 
modelling) and Table 5 (multivariable 
modelling). Two multivariable models are 
shown in Table 5 and these relate to models 
5 and 6 described in the methods. Model 5 
included all relevant variables, but did not 
adjust for clustering by patient. Model 6 did 
adjust for clustering by patient, but it was not 
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Table 5. Prescription-level multivariable models of risks associated with prescribing or monitoring errors:  
unadjusted and adjusted for patient clustering
  Multivariable unadjusted model (model 5)a   Multivariable adjusted model (model 6)b 
Factor Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Medication on monitoring list 3.18 2.05 to 4.94 <0.001 3.63 2.65 to 4.98 <0.001
Repeat prescriptionc 1.25 0.91 to 1.72 0.168 0.98 0.73 to 1.31 0.903
Formulationd       
  Eye/ear drops 1.43 0.39 to 5.23 0.586    
  Inhalers 0.51 0.21 to 1.27 0.149    
  Injections 0.41 0.06 to 3.07 0.387    
  Liquid oral 1.08 0.60 to 1.95 0.794    
  Rectal 1.93 0.24 to 15.42 0.535    
  Topical 0.66 0.31 to 1.42 0.287   
Prescriber typee       
  Salaried GP 0.71 0.46 to 1.11 0.13 0.76 0.47 to 1.22 0.258 
  Locum GP 1.16 0.60 to 2.28 0.655 1.23 0.60 to 2.54 0.576 
  Training GP 1.42 0.67 to 3.01 0.353 1.66 0.74 to 3.72 0.218 
  Non-medical prescriber 1.55 0.47 to 5.13 0.469 1.09 0.30 to 3.91 0.898 
  Other/unknown 1.78 0.52 to 6.14 0.358 1.97 0.54 to 7.23 0.305
British National Formulary chapterf      
  Cardiovascular system 2.37 1.03 to 5.45 0.042    
  Respiratory system 2.26 0.83 to 6.17 0.11    
  CNS 2.09 0.95 to 4.63 0.068    
  Infections 2.67 1.17 to 6.11 0.02    
  Endocrine 1.91 0.78 to 4.72 0.159    
  Obstetrics, gynaecology, 1.41 0.41 to 4.80 0.584 
    urinary tract disorders       
  Malignant disease and 6.77 1.71 to 2 6.84 0.006 
    immunosuppression 
  Nutrition and blood 1.22 0.36 to 4.15 0.752    
  Musculoskeletal 6.97 3.06 to 15.88 <0.001    
  Eye 4.92 1.12 to 21.62 0.035   
  Ear nose and oropharynx 4.60 1.29 to 16.42 0.019   
  Skin 5.78 2.04 to 16.36 0.001   
  Immunology and vaccines 5.91 0.60 to 58.00 0.127  
Computer systemg       
  EMIS PCS 1.06 0.79 to 1.42 0.706 1.13 0.80 to 1.60 0.501 
  Isoft Premiere 0.68 0.46 to 1.01 0.055 0.64 0.40 to 1.01 0.058 
  TPP 1.05 0.71 to 1.56 0.803 0.94 0.58 to 1.52 0.81
CNS = central nervous system. aModel unadjusted for clustering by patient. bModel adjusted for clustering by patient but formulation and chapter not included in the model due 
to non-convergence of model. cAcute prescriptions. dSolid oral medication (pessaries category omitted). eGP partner. fGastrointestinal (anaesthesia chapter omitted). gEMIS LV.
possible to include ‘formulation’ and ‘British 
National Formulary chapter’, owing to model 
non-convergence. Both models showed 
that prescribing a drug on the ‘monitoring 
list’ (see Box 1 for examples) was associated 
with a more than threefold increased risk of 
error (for model 6, OR = 3.63, 95% CI = 2.65 
to 4.98, P<0.001). Neither model showed 
a significant association between the type 
of prescriber or type of computer system 
and prevalence of error. Model 5 showed 
that prescriptions from the following 
British National Formulary chapters were 
significantly associated with excess risk of 
prescribing or monitoring errors compared 
to the gastrointestinal reference category: 
cardiovascular system (OR = 2.37, 95% 
CI = 1.03 to 5.45, P = 0.042), infections 
(OR = 2.67, 95% CI = 1.17 to 6.11, P = 0.02), 
malignant disease and immunosuppression 
(OR = 6.77, 95% CI = 1.71 to 26.84, P = 0.006), 
musculoskeletal (OR = 6.97, 95% CI = 3.06 
to 15.88, P<0.001), eye (OR = 4.92, 95% 
CI = 1.12 to 21.62), ear nose and oropharynx 
(OR = 4.60, 95% CI = 1.29 to 16.42, P = 0.019), 




The prevalence of prescriptions with 
prescribing or monitoring errors found in 
the study was 4.9%. Around one in six of 
the population studied were exposed to a 
prescribing or monitoring error if they had 
been prescribed any medication during the 
12-month data-collection period. Given that 
the study used a sample of practices and 
patients that was reasonably representative 
of England, it is believed that these figures 
give an estimate of the likely prevalence of 
prescribing and monitoring errors across 
the country. The vast majority of the errors 
were judged to be of minor or moderate 
severity, with one in 550 prescriptions 
associated with a severe error.
Strengths and limitations
The 15 general practices included in the 
study were reasonably representative of 
English general practices in terms of list 
size, number of GPs per practice, age 
profile, and points achieved in the Quality 
and Outcomes Framework, although 
they were more deprived. The sampling 
strategy enabled GP training practices 
and dispensing practices to be included. 
Compared with overall figures for England, 
the practices were more deprived.
To avoid any problems with sampling bias 
at the practice level, a random sample of 
patients was obtained from each practice. 
However, it is possible that the recruited 
practices had relatively high levels of 
interest in prescribing compared with 
other practices, and a greater openness 
to external scrutiny of potential prescribing 
errors, which could have caused the 
study to underestimate the true rate of 
prescribing errors. The pharmacists who 
collected data for the study all had clinical 
experience and were provided with training 
in identifying errors. Nevertheless, it is 
possible that they varied in their ability to 
detect potential prescribing and monitoring 
errors. A validated approach to the 
definition of error was used in the study, 
and a multidisciplinary panel was used to 
decide whether an error was present or 
not. A consistent approach was also used 
throughout the study to the application of 
the error definitions used. Nevertheless, 
it is possible that a different panel would 
have come to different judgements, and 
this highlights one of the challenges of 
consistent application of error definitions 
across studies. The present study focused 
on errors associated with prescribing 
and blood test monitoring. With more 
resources, it would have been helpful to 
have investigated errors associated with 
other aspects of medicines management 
in primary care, as done recently in English 
care homes.6
The multivariable analysis undertaken 
allowed associations between the 
prevalence of prescribing and monitoring 
errors and a range of factors to be 
explored, while taking account of potential 
confounders. Statistical significance for all 
analyses was set at <0.05 (two-sided) and 
some may regard this as relatively weak. 
Nevertheless, many of the findings were 
highly statistically significant.
Comparison with existing literature
This study was larger than previous UK 
studies, and used robust methods and 
definitions. The error rates are in line with 
those reported previously,3–6 but the large 
and representative sample makes the 
estimates more precise. The most recent 
of previous studies found a prevalence of 
prescribing error of 8.3% and monitoring 
error of 14.7%,7 albeit it in residential and 
nursing home patients.7 In contrast, the 
prevalence of prescribing errors in UK 
hospitals was 8.9%,15 and in a US hospital 
was 6.2%.16 Internationally, prescribing 
errors affect a median of 7% (IQR = 2–14) of 
medication orders in hospitals.17
The prevalence of prescribing or 
monitoring errors was particularly high in 
certain groups of patients: older people, 
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children, men, and those on multiple 
medications. The high prevalence in older 
people has been noted elsewhere,6 and is 
of particular concern because of greater 
susceptibility of older people to experiencing 
medication-related harm. The high 
prevalence in children highlights the need 
to ensure that correct doses are prescribed 
with clear dosage instructions, but despite 
concerns from another study, off-label and 
unlicensed prescribing was not found to be 
an important cause of error.18 The finding 
that patients taking multiple medications 
have increased risk of error (an association 
that went beyond the additive effect of each 
medicine) is of concern, especially as those 
taking 10 or more medicines had an almost 
50% risk of an error during a 12-month 
period. These findings support those of 
other studies,19 and highlight the need 
to find more effective ways of managing 
polypharmacy.20 The lower risk of error 
in women is a surprising finding, and is in 
contrast to findings suggesting that women 
are at greater risk of adverse drug events.21 
It is possible, however, that GPs are more 
cautious when prescribing for women, 
hence the lower risk of error.
Drugs associated with a higher risk of error 
included those requiring a monitoring test, 
musculoskeletal drugs (most commonly 
non-steroidal antiinflammatory drugs), 
and those used for malignant disease and 
immunosuppression (although the sample 
was small in this last group). This highlights 
the need for GPs to pay particular attention 
to correct prescribing and monitoring of 
medications associated with the highest risk 
of error (and associated adverse events). 
Some of the most serious errors related to 
the prescription of warfarin without access 
to blood-test monitoring (Box 2). Given the 
dangers associated with this drug, it is 
essential that prescribers have access to 
the latest international normalised ratio 
before prescribing, and adhere to local and 
national policies.22 In addition, this study 
identified two cases in which drugs were 
prescribed for patients with a computer-
recorded allergy to the drug. Given the 
design of GP computer systems, it is almost 
certain that these prescribers would have 
overridden a hazard alert. Therefore, there 
is a need to make it more difficult for 
prescribers to override alerts for the most 
serious hazards.23
In addition to the points made above, 
there are several other approaches by which 
prescribing and monitoring errors could 
be reduced in general practices, based on 
the findings of this study. Given that the 
most common type of error detected in the 
study was ‘incomplete dosage instructions’, 
it is important for GPs to take the time 
needed to provide clear and complete 
instructions, particularly for high-risk 
medicines. To help with this, the latest GP 
computer systems are able to provide ‘order 
sentences’ (dosage instructions) that are 
appropriate for each medication prescribed. 
Greater use of this functionality by GPs 
could substantially reduce error rates. 
Given that monitoring errors are another 
common category of error, it is important 
for general practices to ensure that they 
have robust systems in place to make sure 
that essential blood-test monitoring is 
done. GP computer systems can help with 
identifying patients who need monitoring, 
and this can also be done at prescription 
reviews. These reviews can also act as an 
opportunity to identify and correct errors, 
but the present study showed that repeat 
prescriptions were no less likely to contain 
an error than acute prescriptions. This 
suggests that prescription reviews may not 
be as effective as they could be, especially 
in patients taking multiple medications, and 
in higher-risk complex patients. It may be 
helpful to consider different models for 
conducting these reviews. For example, 
involving pharmacists and geriatricians in 
the review of older patients on multiple 
medications may help reduce unnecessary 
polypharmacy,20 and also reduce errors. 
Pharmacists can also help GPs to reduce 
prescribing errors by identifying patients at 
risk (based on searches of the GP computer 
system), and facilitating appropriate 
management of any problems identified.24 
This approach, would be suitable for 
tackling some of the errors observed in 
this study, particularly monitoring errors. 
Overall, there is considerable scope for GP 
computer systems to help reduce many of 
the prescribing errors identified in this study. 
In addition to points made already, the most 
advanced systems can help provide advice 
on correct dosage, based upon a patient’s 
age, weight, and/or renal function. They 
can also provide alerts for contraindicated 
prescribing. A key challenge, however, is 
to avoid over-alerting prescribers, and to 
design systems to minimise the risk of 
accidentally overriding alerts for potentially 
fatal errors.
It should be noted that the study 
reported in this paper was part of a larger 
investigation funded by the General Medical 
Council (GMC) in the UK, and further details 
are available from the GMC website.25
Implications for future research
Further research is now needed to develop 
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and test interventions to reduce the 
prevalence of prescribing and monitoring 
errors in general practices. It is already 
known that computerised clinical decision 
support can help reduce prescribing errors 
in hospitals,26 but there is a need for more 
studies in primary care, particularly to 
evaluate the more sophisticated systems in 
current use and to determine whether there 
are safety benefits to reducing the hazard-
alert burden on prescribers. Further 
research is also needed into whether the 
prevalence of prescribing and monitoring 
errors in general practice can be reduced 
by education, training, audit, and practical 
support, as demonstrated previously.24 It is 
also important to evaluate the effectiveness 
of systems-based approaches to reducing 
prescribing and monitoring errors whereby 
processes used in general practices such 
as repeat prescribing, medication review, 
and monitoring are optimised. Finally, it 
would be helpful to do further research 
to determine the extent to which the 
prevalence of prescribing and monitoring 
errors can be reduced by more extensive 
involvement of clinical pharmacists in 
promoting high-quality, safe prescribing 
in general practice. For example, a model 
could be developed in which pharmacists 
work with GPs to address the most 
important factors associated with error.
Prescribing or monitoring errors 
occurred in one in 20 prescription items, 
and most of these were judged to be of 
mild to moderate severity; one in 550 
prescription items contained a severe error. 
The risks of error were higher in children, 
older people, male patients, and those on 
multiple medications. Several groups of 
drugs were associated with higher risks 
of error, including those requiring blood-
test monitoring. Having identified the most 
common and important errors, and the 
factors associated with these, strategies to 
prevent future errors should be developed, 
based on the study findings.
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